Skip to main content
Smaller Larger Print

MENU

Myeloproliferative Neoplasm NGS Screening Panel

Requires patient informed consent

Sample Reqs

Aor bone marrow aspirate sample

Turnaround

1 week

Special instructions

No special instructions.



Sample type guide

A

Lavender Vacutainer, EDTA anticoagulant, 3ml minimum

Test details

This next-generation sequencing (NGS) panel enables the analysis of 45 DNA targets (see below), producing a comprehensive profile of myeloid mutations from a single NGS run.

Gene content on the panel has been curated to cover relevant targets for all the major myeloid disorders – acute myeloid leukaemia (AML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPNs), chronic myeloid leukaemia (CML), chronic myelomonocytic leukaemia (CMML), and juvenile myelomonocytic leukaemia (JMML).

Among the targets are Calreticulin (CALR), JAK2, MPL and NPM1, which were previously offered as individual tests.

 

DNA – 28 hotspot genes ANKRD26, ABL1, BRAF, CBL, CSF3R, DDX41, DNMT3A, FLT3 (ITD, TKD), GATA2, HRAS, IDH1, IDH2, JAK2, KIT, KRAS, MPL, MYD88, NPM1, NRAS, PPM1D, PTPN11, SMC1A, SMC3, SETBP1, SF3B1, SRSF2, U2AF1, WT1.
DNA - 17 full genes ASXL1, PRPF8, BCOR, RB1, CALR, RUNX1, CEBPA, SH2B3, ETV6, STAG2, EZH2, TET2, IKZF1, TP53, NF1, ZRSR, PHF6.
DNA – 5 expression genes BAALC, MECOM, MYC, SMC1A, WT1.
DNA – 5 expression control genes EIF2B1, FBXW2, PSMB2, PUM1, TRIM27.
DNA Panel (45 genes)  
Additional information

Last-updated: 13/03/23

 

Back to test list